TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27741367
Drug: Investigational cigarette
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational cigarette with 0.4 mg/g nicotine content
Study: 24113764
Drug: Transdiagnostic Internet‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdiagnostic Internet‐based maintenance treatment (TIMT)
Study: 21835552
Drug: Post-discharge behavioral
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-discharge behavioral treatment
Study: 11252284
Drug: Attitudes and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Attitudes and behaviors associated with alcohol and drug problems like stimulus seeking, rule violations and bad judgement
Study: 8109762
Drug: Intrathecal 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal 2.5 mg bupivacaine + 22.2 +/- 4.6 mL epidural lidocaine
Study: 8109762
Drug: Intrathecal 5
Normalized name: ZICONOTIDE 100MCG/ML INJ INTRATHECAL 5ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal 5 mg bupivacaine + 10.1 +/- 2.0 mL epidural lidocaine
Study: 8109762
Drug: Intrathecal 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal 7.5 mg bupivacaine
Study: 8109762
Drug: Intrathecal 10
Normalized name: LIORESAL INTRATHECAL 10 MG in 20 ML (500 MCG/ML) Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal 10 mg bupivacaine
Study: 2842144
Drug: Flumazenil (0.001,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil (0.001, 0.003, 0.007 or 0.014 mg kg-1)
Study: 26261386
Drug: fluconazole 150
Normalized name: fluconazole 150 MG
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: fluconazole 150 mg 1x weekly
Study: 26261386
Drug: itraconazole continual
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: itraconazole continual therapy
Study: 26261386
Drug: itraconazole pulse
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: itraconazole pulse therapy
Study: 26261386
Drug: terbinafine 250
Normalized name: terbinafine 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: terbinafine 250 mg/d
Study: 19555446
Drug: Prebiotic mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prebiotic mixture (0.8 g/dL of scGOS and lcFOS, ratio 9:1)
Study: 31077311
Drug: Cisplatin/gemcitabine chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin/gemcitabine chemotherapy
Study: 23183442
Drug: Intramuscular quinine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular quinine (loading dose of 20 mg quinine dihydrochloride/kg)
Study: 16448867
Drug: Methyldopa preparation
Normalized name: Methyldopa
DrugBank: Methyldopa (DB00968)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methyldopa preparation 1
Study: 16448867
Drug: Methyldopa preparation
Normalized name: Methyldopa
DrugBank: Methyldopa (DB00968)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methyldopa preparation 2
Study: 8929256
Drug: pravastatin 40
Normalized name: pravastatin 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: pravastatin 40 mg o.d.
Study: 8929256
Drug: gemfibrozil +
Normalized name: Gemfibrozil
DrugBank: Gemfibrozil (DB01241)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: gemfibrozil + pravastatin (same doses)
Study: 1404679
Drug: Enteric-coated aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric-coated aspirin or low-dose aspirin (80 to 325 mg daily)
Study: 1404679
Drug: Overall aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Overall aspirin usage
Study: 3981950
Drug: Low molecular-weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular-weight heparin (LMW heparin) at 50% of the normal unfractionated heparin (UF heparin) dose
Study: 3981950
Drug: Low molecular-weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular-weight heparin (LMW heparin)
Study: 3981950
Drug: UF heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: UF heparin and LMW heparin
Study: 3286383
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (UDCA) 11.1 mg/kg per day (group A)
Study: 3286383
Drug: Ursomenth (UDCA/menthol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursomenth (UDCA/menthol mixture: 4.75 mg/kg per day each) (group B)
Study: 30916194
Drug: β1 specific
Normalized name: PACIFIC OYSTER
Approvals — FDA: no, EMA: no, PMDA: no
Description: β1 specific beta-blockers + alpha 1-blocker
Study: 30916194
Drug: β1 non-specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: β1 non-specific beta-blockers
Study: 23499394
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (lukewarm water foot bath)
Study: 21545249
Drug: Inhaled montelukast
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled montelukast 1 mg plus inhaled mometasone 220 μg
Study: 21545249
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus inhaled mometasone 220 μg
Study: 19789401
Drug: Intracoronary administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary administration of bone marrow-derived mononuclear cells (BMC) within 7 days after successful reperfusion therapy for AMI.
Study: 16730616
Drug: Terbinafine 250
Normalized name: terbinafine 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbinafine 250 mg/d for 12 weeks
Study: 16730616
Drug: Terbinafine 250
Normalized name: terbinafine 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbinafine 250 mg/d for 12 weeks with aggressive toenail debridement
Study: 2826526
Drug: Insulin (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin (0.1 U/kg, iv) followed by placebo
Study: 2826526
Drug: Insulin (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin (0.1 U/kg, iv) followed by oral clonidine (0.150 mg)
Study: 2826526
Drug: Oral clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral clonidine (0.150 mg) followed by iv placebo
Study: 2826526
Drug: Oral clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral clonidine (0.150 mg) followed by iv insulin (0.1 U/kg)
Study: 22111770
Drug: Daily supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily supplementation with multiple micronutrient powder (MMP) for 24 weeks (n = 111)
Study: 22111770
Drug: Twice weekly
Normalized name: Alora 0.1 MG/Day Twice Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice weekly supplementation with multiple micronutrient powder (MMP) for 24 weeks (n = 115)
Study: 19271165
Drug: Xinyue Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xinyue Capsule (XYC) plus Composite Salvia Tablet (CST)
Study: 16971855
Drug: 4% human
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% human albumin with >3 L of fluids in the first 24 hrs
Study: 15563344
Drug: Caffeine (1.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (1.75 mg/kg) three times daily for 4 consecutive weeks
Study: 9394856
Drug: Anastrozole, 1
Normalized name: Anastrozole, 1 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anastrozole, 1 mg once daily, orally
Study: 9394856
Drug: Formestane, 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formestane, 250 mg every 2 weeks, intramuscularly
Study: 28931197
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone 0.4 mg/kg/day for 4 weeks, tapered to 0.2 mg/kg/day for 2 months, and to 0.1 mg/kg/day for the last 2 months (Group A)
Study: 28931197
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone tapered within 2 months (Group B)
Study: 25348255
Drug: LY500307 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY500307 1 mg
Study: 25348255
Drug: LY500307 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY500307 3 mg
Study: 25348255
Drug: LY500307 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY500307 10 mg
Study: 25348255
Drug: LY500307 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY500307 25 mg
Study: 23989256
Drug: Minodronate (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minodronate (1.0 mg daily)
Study: 23989256
Drug: Risedronate (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate (daily treatment combined with 1000 IU ergocalciferol and 1200 mg elemental calcium)
Study: 21341397
Drug: S-equol (10-320
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-equol (10-320 mg single dose)
Study: 21341397
Drug: S-equol (10-160
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-equol (10-160 mg, BID for 14 days)
Study: 21341397
Drug: S-equol (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-equol (20 mg single dose with food)
Study: 21341397
Drug: S-equol (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-equol (various doses)
Study: 21341397
Drug: S-equol (320
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-equol (320 mg single dose)
Study: 15310633
Drug: Tandospirone 10
Normalized name: Tandospirone
DrugBank: Tandospirone (DB12833)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tandospirone 10 mg
Study: 8995995
Drug: Nebulized albuterol
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized albuterol (5 mg) - single dose
Study: 8995995
Drug: Nebulized albuterol
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized albuterol (5 mg) - double dose
Study: 8355469
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (15 g/day)
Study: 3117876
Drug: Clomipramine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomipramine (150 mg)
Study: 29906273
Drug: 25-hydroxyvitamin D
Normalized name: 25-hydroxyvitamin D
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25-hydroxyvitamin D concentrations ≥60 ng/ml
Study: 29906273
Drug: 25-hydroxyvitamin D
Normalized name: 25-hydroxyvitamin D
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25-hydroxyvitamin D concentrations <20 ng/ml
Study: 19664300
Drug: High-wheat fibre
Normalized name: WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-wheat fibre cereal (24 g fibre/d)
Study: 11563413
Drug: Rizatriptan (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rizatriptan (1 mg) with Paroxetine (20 mg once daily)
Study: 11563413
Drug: Rizatriptan (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rizatriptan (1 mg)
Study: 7554037
Drug: CPT-11 AUC
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPT-11 AUC (ng h ml-1) using a trivariate model: CPT‐11 AUC = 0.820 x C0.5h + 0.402 x C1h + 15.47 x C6h + 928
Study: 7554037
Drug: SN-38 AUC
Normalized name: sn-3-GPC
DrugBank: Choline alfoscerate (DB04660)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SN-38 AUC (ng h ml-1) using a trivariate model: SN‐38 AUC = 4.05 x C0.5h ‐0.81 x C1h + 23.01 x C6h ‐ 69.78
Study: 30393935
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment (ATRA, cytarabine, anthracyclines)
Study: 29450452
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy plus regional hyperthermia
Study: 22825691
Drug: Paclitaxel (175
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (175 mg/m2 intravenously over 3 h) plus Carboplatin (AUC 5 intravenously over 30 min)
Study: 20178395
Drug: Personalized letter
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized letter from a practicing pharmacist containing treatment recommendations for patients with upcoming primary care visits (intervention group, n = 150)
Study: 17141481
Drug: Anti-Helicobacter pylori
Normalized name: Anti-Helicobacter pylori IgG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-Helicobacter pylori treatment (clarithromycin, amoxicillin, lansoprazole)
Study: 17141481
Drug: Probiotic combination
Normalized name: PROBIOTIC COMBINATION CAP/TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic combination (Lactobacillus rhamnosus GG, L. rhamnosus LC705, Propionibacterium freudenreichii ssp. shermanii JS, Bifidobacterium breve Bb99)
Study: 15657401
Drug: Maintenance rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Maintenance rituximab therapy (standard 4-week courses administered at 6-month intervals)
Study: 15657401
Drug: Rituximab re-treatment
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab re-treatment at progression
Study: 7794307
Drug: Nystatin 50,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nystatin 50,000 U/kg four times daily
Study: 7794307
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B 25 mg/kg four times daily
Study: 3277911
Drug: OKY‐046 (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: OKY‐046 (400 mg)
Study: 3277911
Drug: OKY‐046 (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: OKY‐046 (600 mg/day for 3 days)
Study: 3277911
Drug: Captopril (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (50 mg) + OKY‐046
Study: 30203101
Drug: Standard triamcinolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard triamcinolone acetonide crystalline suspension (TAcs) 40 mg
Study: 18061001
Drug: New antiarrhythmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: New antiarrhythmic drugs
Study: 10783213
Drug: Hospital discharge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hospital discharge while taking a beta-blocker
Study: 10783213
Drug: Hospital discharge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hospital discharge while taking an angiotensin-converting enzyme inhibitor
Study: 3886402
Drug: Cadralazine 15
Normalized name: cadralazine
DrugBank: Cadralazine (DB13452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cadralazine 15 mg/day
Study: 30326380
Drug: Methadone 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone 0.1 mg kg-1
Study: 30326380
Drug: Morphine 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 0.1 mg kg-1
Study: 18940484
Drug: E‐L pretreatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: E‐L pretreatment (epinephrine and lidocaine mixture)
Study: 16088363
Drug: High-dose simvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose simvastatin (80 mg/daily)
Study: 16088363
Drug: Pravastatin 40
Normalized name: pravastatin 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 40 mg/daily
Study: 16088363
Drug: Simvastatin 20
Normalized name: simvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 20 mg/daily
Study: 12017384
Drug: Isoflurane administration
Normalized name: Isoflurane
DrugBank: Isoflurane (DB00753)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoflurane administration via microporous capillary membrane oxygenator
Study: 12017384
Drug: Isoflurane administration
Normalized name: Isoflurane
DrugBank: Isoflurane (DB00753)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoflurane administration via diffusion membrane oxygenator
Study: 10080835
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose BCG
Study: 10080835
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose BCG
Study: 10080835
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose BCG with IFN-alpha
Study: 10080835
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment arms (High dose BCG, Low dose BCG, Low dose BCG with IFN-alpha)
Study: 10080835
Drug: Intravesical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical treatment
Study: 7590403
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (50 mg zinc as 220 mg zinc sulphate daily for 4 weeks)
Study: 31761416
Drug: Ultrasound-guided bilateral
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided bilateral superficial cervical plexus block with 10 ml of ropivacaine 0.5%
Study: 23572466
Drug: Very low
Normalized name: Very low fat spread
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very low dose naltrexone (VLNTX) added to methadone taper
Study: 23572466
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of VLNTX and clonidine
Study: 23572466
Drug: In-treatment smokers
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-treatment smokers (n = 96)
Study: 19597420
Drug: Early administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early administration of rhG‐CSF (4th day)
Study: 19597420
Drug: Late administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Late administration of rhG‐CSF (7th day)
Study: 17368530
Drug: Homeopathic care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homeopathic care (HC: individual homeopathic consultations with any homeopathic medicine in any potency being prescribed)
Study: 17368530
Drug: Self-prescribed homeopathic
Normalized name: Urtica urens homeopathic preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-prescribed homeopathic medicine (SPH) in C-30 administered twice weekly for 12 weeks
Study: 17368530
Drug: Self-prescribed homeopathic
Normalized name: Urtica urens homeopathic preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-prescribed homeopathic medicine (SPH)
Study: 15353916
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (LMWH) administered subcutaneously in a fixed daily dose
Study: 15353916
Drug: Conventional oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional oral anticoagulant therapy (OAT)
Study: 8490638
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral group psychotherapy with treatment intensity (high and low)
Study: 24888929
Drug: Early oral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early oral feeding (liquid diets commenced 2 hours after surgery)
Study: 24888929
Drug: Delayed oral
Normalized name: lipase 12,000 UNT / amylase 39,000 UNT / protease 39,000 UNT Delayed Oral Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed oral feeding (liquid diets commenced 8 hours after surgery)
Study: 1774568
Drug: Low-dose warfarin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose warfarin (LDW)
Study: 6124654
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of 20 mg clorazepate dipotassium (CZP)
Study: 6124654
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of 20 mg clorazepate dipotassium (CZP)
Study: 6124654
Drug: Intramuscular administration
Normalized name: Japanese Encephalitis vaccine for intramuscular administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular administration of 20 mg clorazepate dipotassium (CZP)
Study: 24680796
Drug: Sildenafil 50
Normalized name: sildenafil 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil 50 mg daily for 8 weeks
Study: 9924274
Drug: Moderately-fatty breakfast
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderately-fatty breakfast (25.7 g fat; M)
Study: 9924274
Drug: Low-fat high-carbohydrate
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fat high-carbohydrate breakfast (5.5 g fat; L)
Study: 8036679
Drug: Mefloquine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mefloquine (15 mg/kg) plus artesunate (10 mg/kg)
Study: 8036679
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose mefloquine (25 mg/kg)
Study: 29676968
Drug: Low-dose milk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose milk (120 mg/100 mL calcium, vitamin D3 30 UI/100 mL)
Study: 29676968
Drug: Group A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: milk (180 mg/100 mL calcium, 120 UI/100 mL vitamin D)
Study: 29676968
Drug: Group B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B: milk (180 mg/100 mL calcium, 120 UI/100 mL vitamin D) and FOS (5 g/L)
Study: 27380030
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg of TAU
Study: 23312049
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (rosuvastatin + fenofibric acid)
Study: 18756744
Drug: Traditional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional therapy only
Study: 14506629
Drug: Troglitazone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troglitazone (200 mg/d)
Study: 8767437
Drug: Omeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (20 mg twice a day) for group 3
Study: 8767437
Drug: Cisapride (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride (30 mg) for group 2
Study: 8767437
Drug: No drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: No drug therapy for group 1
Study: 30266309
Drug: Androgen Deprivation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen Deprivation Therapy (ADT) with External Beam Radiation Therapy (EBRT)
Study: 30266309
Drug: Androgen Deprivation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen Deprivation Therapy (ADT) alone
Study: 29742190
Drug: Cream-to-powder product
Normalized name: tolnaftate
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cream-to-powder product
Study: 20678687
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination (FDC) tablet of glimepiride/metformin 2/500 mg
Study: 20678687
Drug: Separate tablets
Normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separate tablets of glimepiride 2 mg + metformin 500 mg